Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics

Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics

According to a study conducted by the World Health Organization (WHO), diseases that affect the central nervous system (CNS), such as Alzheimer’s disease, brain cancer, multiple sclerosis, Parkinson’s disease and stroke, are characterized by a significant unmet need for effective treatment options. In 2019, it was reported that nearly 1.5 billion people suffer from some form of disorder affecting the CNS across the globe. , , In fact, the incidence of CNS disorders is anticipated to increase by 12% by 2030. In 2019, nearly 5.8 million Americans were reported to have been diagnosed with Alzheimer’s disease. , Similarly, Parkinson’s disease was estimated to affect nearly one million people in America, with approximately 60,000 new patients being diagnosed every year. It was estimated that CNS disorders are responsible for a healthcare burden of nearly USD 2 trillion, in the US and Europe. Developing viable therapies against the aforementioned clinical conditions is largely complicated due to the elusive blood-brain barrier (BBB), a selectively permeable structure, which is very effective in preventing the entry of foreign substances, including drugs, into the brain. It has been reported that over 1,000 currently available / under development drugs targeting CNS disorders do not have the potential to target specific brain receptors responsible for the disease progression due to the hindrance by the BBB. Considering the serious physical, cognitive and psychosocial consequences that such indications have on patients, coupled to the alarming increase in their global prevalence, there is an urgent need for novel and effective treatment options that can cross the BBB.

Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the BBB or augment the BBB penetrating capabilities of compatible pharmacological interventions. As a result, presently, there is a lot of enthusiasm within the medical science community related to these technologies. The growing interest in this field is also evident in the fact that over 1,200 modern scientific articles have been published (as observed on NCBI’s PubMed portal) over the last three years alone. However, it is worth mentioning that there are currently no approved BBB penetrating drugs available in the market. Currently, this niche market is driven by technology licensing activity, with drug developers collaborating with platform providers to grow their respective therapeutic pipelines. In fact, over the last 4-5 years, there has been a marked rise in the number of new entrants in this field. We anticipate this upcoming market to witness substantial growth in the coming years.

The ‘Blood-Brain Barrier (BBB) Market, 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics (2nd Edition) (based on Receptor Mediated Transcytosis, Trojan Horse, and Nanoparticle based Approaches)’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
 An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters, such as status of development (developed and under development), affiliated approach, type of compatible pharmacological molecule(s) crossing the BBB (small molecule and biologic), target receptor(s), target disease indication(s), patent availability, and licensing activity. In addition, it presents a detailed assessment of BBB technology developers and analyses based on parameters, such as year of establishment, company size, and location of headquarters.
 A detailed assessment of the current market landscape of BBB penetrant drugs (based on the abovementioned technologies), providing information on drug developer(s) (such as year of establishment, company size, and location of headquarters), phase of development (clinical, preclinical, and discovery stage), type of molecule (small molecule and biologic), affiliated BBB penetration technology, route of administration (oral, intravenous, transmucosal and others), target disease indication(s), key therapeutic area(s), and information on special drug designation (if any).
 Identification of contemporary market trends, depicted using three schematic representations, which include [A] a tree map representation of the various industry players involved in the development of BBB penetrant drugs, distributed on the basis of the target disease indication(s) of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a bubble analysis comparing the leading players engaged in the development of BBB penetrant drugs, on the basis of parameters such as pipeline strength (based on the number of drug candidates developed by a particular company, across different phases of development), number of target disease indication(s) and the size of the developer company, and [C] an informative heptagon representation, highlighting the distribution of BBB penetrant drugs across popular target disease indication(s) (based on the number of drug candidates across each target disease indication).
 An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power (based on company size and years of experience in this field) and key technology specific information, such as type of compatible pharmacological molecule(s) crossing the BBB, availability of patent protection, number of deals signed for a particular technology (2014-2020 (till March)), and popularity of the technology (in terms of the number of drugs developed using the technology).
 Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs (which are presently in both preclinical and clinical stages of development), featuring a brief overview of the company, its financial information (if available), BBB penetration technology overview, BBB penetrant product portfolio and an informed future outlook.
 An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020 (till March), covering product licensing agreements, technology licensing agreements, acquisitions and mergers, product development and commercialization agreements, research and development agreements, manufacturing agreements, service agreements and other agreements.
 An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain, including details of the rights associated with product ownership, associated royalties and upfront payments, and other contractual terms / conditions involved as a part of the agreement between various industry stakeholders.
 An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field.
 An in-depth analysis of the various patents that have been filed / granted related to BBB penetration technologies, till November 2019, taking into consideration various parameters, such as patent type, application year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, type of organization and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
 An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.
 An assessment of the most commonly targeted disorders affecting the CNS (shortlisted on the basis of number of BBB penetrant drugs in development), along with [A] an insightful 3D bubble chart highlighting the market potential of these disorders, based on the number of already approved drugs, number of pipeline drugs and the target patient population, and [B] an elaborate discussion on key epidemiological facts about specific diseases, causes, symptoms, details of BBB penetrant drugs that are being developed against them, currently available treatment options and details of already marketed drugs for each indication.
 A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers, and have been shortlisted on the basis of parameters, such as developer strength (based on company size and years of experience in this field), company’s pipeline strength and maturity (based on the number of drugs and affiliated stage of development), indication overlap, molecule type overlap, route of administration, mechanism of action, and the availability of in-house delivery technology.
 A case study highlighting the working principle of the most common approaches that are being employed for the development of BBB penetration technologies, such as receptor mediated transcytosis (RMT) (including bispecific antibodies and molecular trojan horse mediated delivery either by direct coupling or using nanocarriers), increasing permeability to the BBB, passive diffusion approach, and other novel approaches (including cell-penetrating peptides, macrocycles, and organ-on-a-chip technology).
 An informative analysis of contemporary Google Trends in the time period between 2015 and 2019 (till December) and insights generated from recent news articles related to the BBB, indicating the increasing popularity of this domain.
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for BBB penetration technologies and affiliated therapeutics, over the next decade. Based on likely licensing deal structures and agreements that are expected to be inked in the foreseen future, we have provided an informed estimate of the evolution of the market for the period 2020-2030. In addition, we have provided information on (potential) sales-based revenues generated by BBB penetrant drugs that are currently in late stages of development for the treatment of different CNS disorders, based on parameters, such as target consumer segments, likely adoption rates, expected pricing and associated risk-adjustment sales opportunity. The report also features the likely distribution of the current and forecasted opportunity across [A] type of molecule (small molecules and biologics), [B] target disease indications (brain metastases in breast cancer, glioblastoma multiforme, Hurlers syndrome, and Hunter syndrome), [C] key contributing technologies, [D] leading drug developers, and [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for the uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
 Ram Bhatt (Chief Executive Officer, Chairman and Founder, Innovative California Biosciences International (ICBI))
 Frank S Walsh (Chief Executive Officer and Founder, Ossianix)
 Pieter Gaillard (Chief Executive Officer and Co-Founder, 2-BBB)
 Mathias Schmidt (Chief Executive Officer, ArmaGen)
 Rob Hutchison (Chief Executive Officer and Chairman, biOasis Technologies)
 Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)
 Xavier Rivero (Chief Operating Officer, Sagetis Biotech)
 Carole Desseaux (Head of Clinical Affairs, CarThera)
 Jamal Temsamani (Head of Drug Development, Vect-Horus)
 Kevin Kit Parker (Professor, Wyss Institute, Harvard University)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views
While the focus has been on forecasting the market till 2030, the report also provides our independent view on technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of BBB penetration technologies and therapeutics market and its likely evolution in the short-mid term and long term.

Chapter 3 is an introductory chapter that highlights important concepts related to the structure of human brain, its components and their functions in the central nervous system (CNS). It also presents an elaborate discussion on the different invasive and non-invasive strategies used to deliver drugs into the CNS. Further, the chapter provides an overview of the concept of BBB, historical evolution, including its role for efficient drug delivery. Furthermore, it provides information on the popular concepts used to develop BBB permeable drugs and technologies or to bypass the barrier. The chapter also includes a discussion on the key challenges associated with the use of BBB penetration technologies for efficient drug delivery to CNS. Additionally, it includes an analysis of contemporary Google Trends (till 2019) and insights from recent news articles related to the BBB, indicating the increasing popularity of this domain.

Chapter 4 provides a detailed overview of the overall landscape of BBB penetration technology providers. It features an in-depth analysis of the BBB penetration technologies, based on a number of parameters, such as status of development (developed and under development), affiliated approach, type of compatible pharmacological molecule(s) crossing the BBB (small molecule and biologic), target receptor(s), target disease indication(s), patent availability, and licensing activity. In addition, the chapter highlights a detailed landscape of BBB technology developers and analyses based on parameters, such as year of establishment, company size, and location of headquarters.

Chapter 5 includes a detailed assessment of the current market landscape of over 100 BBB penetrant drugs that are currently being evaluated in different stages of development. It features a comprehensive analysis of pipeline molecules based on their phase of development (clinical, preclinical, and discovery stage), type of molecule (small molecule and biologic), affiliated BBB penetration technology, route of administration (oral, intravenous, transmucosal and others), target disease indication(s), key therapeutic area(s), and information on special drug designation (if any). Further, the chapter provides information on drug developer(s), highlighting their year of establishment, company size, and location of headquarters. It also focuses on the identification of contemporary market trends, depicted using three schematic representations, which include [A] a tree map representation of the various industry players involved in the development of BBB penetrant drugs, distributed on the basis of the target disease indication(s) of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a bubble analysis comparing the leading players engaged in the development of BBB penetrant drugs, on the basis of parameters such as pipeline strength (based on the number of drug candidates developed by a particular company, across different phases of development), number of target disease indication(s) and the size of the developer company, and [C] an informative heptagon representation, highlighting the distribution of BBB penetrant drugs across popular target disease indication(s) (based on the number of drug candidates across each target disease indication).

Chapter 6 features elaborate profiles of prominent technology developers that are engaged in the development at least four drugs (which are presently in both preclinical and clinical stages of development). Each company profile features a brief overview of the company, its financial information (if available), BBB penetration technology overview, BBB penetrant product portfolio and an informed future outlook.
Chapter 7 presents a competitiveness analysis of BBB technologies, taking into consideration the supplier power (based on company size and years of experience in this field) and key technology specific information, such as type of compatible pharmacological molecule(s) crossing the BBB, availability of patent protection, number of deals signed for a particular technology (2014-2020 (till March)), and popularity of the technology (in terms of the number of drugs developed using the technology). The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 8 features a discussion on the working principle of the most common approaches being utilized for the development of BBB penetration technologies, such as RMT (including bispecific antibodies and molecular trojan horse mediated delivery either by direct coupling or using nanocarriers), increasing permeability to the BBB, passive diffusion approach, and other novel approaches (including cell-penetrating peptides, macrocycles, and organ-on-a-chip technology).

Chapter 9 features an in-depth analysis and discussion on the various partnerships inked between the players in this market in the time period between 2014 and 2020 (till March), covering product licensing agreements, technology licensing agreements, acquisitions and mergers, product development and commercialization agreements, research and development agreements, manufacturing agreements, service agreements and other agreements.

Chapter 10 provides an elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain, including details of the rights associated with product ownership, associated royalties and upfront payments, and other contractual terms / conditions involved as a part of the agreement between various industry stakeholders.

Chapter 11 presents details on various investments received by companies that are focused on developing BBB penetration technologies and drugs. It also includes an analysis of the funding instances that have taken place in the market, up to 2020 (till March), highlighting the growing interest of the venture capital (VC) community and other strategic investors within this domain.

Chapter 12 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to BBB penetration technologies till November 2019. The analysis also highlights the key trends associated with these patents, across patent type, application year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, type of organization and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
Chapter 13 features an insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers with clinical candidates engaged in this domain. The analysis was designed to enable stakeholder companies to improve their existing drug development strategies in order to accelerate the progress of their lead drug candidates.

Chapter 14 presents an insightful 3D bubble chart highlighting the market potential of the most commonly targeted disorders affecting the CNS (shortlisted on the basis of number of BBB penetrant drugs in development), based on the number of already approved drugs, number of pipeline drugs and the target patient population. It also includes an elaborate discussion on key epidemiological facts about specific diseases, causes, symptoms, details of BBB penetrant drugs that are being developed against them, currently available treatment options and details of already marketed drugs for each respective indication.

Chapter 15 presents a list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers, and have been shortlisted on the basis of parameters, such as developer strength (based on company size and years of experience in this field), company’s pipeline strength and maturity (based on the number of drugs and affiliated stage of development), indication overlap, molecule type overlap, route of administration, mechanism of action, and the availability of in-house delivery technology.

Chapter 16 features a comprehensive market forecast, highlighting the future potential of this market till 2030 based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we have provided information on (potential) sales-based revenues generated by BBB penetrant drugs that are currently in late stages of development for the treatment of different CNS disorders, based on parameters, such as target consumer segments, likely adoption rates, expected pricing and associated risk-adjustment sales opportunity. The chapter also features the likely distribution of the current and forecasted opportunity across [A] type of molecule (small molecules and biologics), [B] target disease indications (brain metastases in breast cancer, glioblastoma multiforme, Hurlers syndrome, and Hunter syndrome), [C] key contributing technologies, [D] leading drug developers, and [E] key geographical regions (North America, Europe, Asia-Pacific and rest of the world).

Chapter 17 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 18 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Ram Bhatt (CEO, Chairman and Founder, Innovative California Biosciences International (ICBI)), Frank S Walsh (CEO and Founder, Ossianix), Pieter Gaillard (CEO And Co-Founder, 2-BBB), Mathias Schmidt (CEO, ArmaGen), Rob Hutchison (CEO and Chairman, biOasis Technologies), Mark L Peterson (Chief Operating Officer, Cyclenium Pharma), Xavier Rivero (Chief Operating Officer, Sagetis Biotech), Carole Desseaux (Head of Clinical Affairs, CarThera), Jamal Temsamani (Head of Drug Development, Vect-Horus), and Kevin Kit Parker (Professor, Wyss Institute, Harvard University)

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 20 is an appendix, which contains the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies / institutes / government bodies and organizations have been mentioned in this report.


1. 2-BBB
2. 2X Oncology (a spin out from Oncology Venture)
3. 4P Therapeutics
4. AB SCIENCE
5. Abbott
6. AbbVie
7. Ablynx
8. AC Immune
9. Acadia Pharmaceuticals
10. Accera
11. Acelot
12. Acorda Therapeutics
13. Actinogen Medical
14. Acumen Pharmaceuticals
15. Adamas Pharmaceuticals
16. Addex Therapeutics
17. Advanced Accelerator Applications (acquired by Novartis)
18. Advanced BioHealing
19. Aeolus Pharmaceuticals
20. Aescap Ventures
21. Aestas Pharma
22. Affectis Pharmaceuticals
23. AFFiRiS
24. Agate Medical Investments
25. AgeneBio
26. Agoranov
27. AiCuris
28. Aix-Marseille University
29. Alaska Permanent Fund
30. Alcyone Lifesciences
31. Alector
32. Alkahest
33. Allergan
34. Allinky Biopharma
35. Alnylam Pharmaceuticals
36. Alzinova
37. AlzProtect
38. Amabiotics
39. Amarantus Therapeutics
40. American Cancer Society
41. American Life Science Pharmaceuticals
42. Amgen
43. Amylyx Pharmaceuticals
44. Anavex Life Sciences
45. Angiochem
46. Antea Group
47. Antoxis
48. Aphios
49. ApoPharma
50. APRINOIA Therapeutics
51. Araclon Biotech
52. Arbor
53. ARCH Venture Partners
54. Archer Pharmaceuticals
55. ArmaGen
56. ARMGO Pharma
57. ArQule
58. Array BioPharma
59. Arrien Pharmaceuticals
60. Arrowhead Pharmaceuticals
61. Artenga
62. Asceneuron
63. ASCIL Biopharm
64. ASEBIO
65. Astellas Pharma
66. AstraZeneca
67. Atlas Venture
68. aTyr Pharma
69. Aurin Biotech
70. Ausio Pharmaceuticals
71. Autifony Therapeutics
72. Avanir Pharma
73. Axon Neuroscience
74. Axovant Sciences
75. Axsome Therapeutics
76. AZTherapies
77. Bach Pharma
78. Baillie Gifford
79. Baxter Healthcare
80. Bayer
81. BBB Therapeutics
82. BDC Venture Capital
83. BELLUS Health
84. BenevolentAI Bio
85. Ben-Gurion University
86. BGN Technologies
87. BIAL Group
88. BIND Therapeutics
89. BioAdvance
90. BioAgilytix
91. BioArctic
92. biOasis Technologies
93. Biocat
94. Biocrea
95. BioElectronic
96. Biogen
97. Biohaven
98. BioLineRx
99. BioMarin
100. Bionomics
101. Biotie Therapies
102. Biovista
103. BlueRock Therapeutics
104. Boehringer Ingelheim
105. Boehringer Ingelheim Venture Fund
106. Boston Scientific
107. BpiFrance
108. Brain Biomarker Solutions
109. Brains for Brain Foundation
110. BrainsGate
111. BrainStorm Cell Therapeutics
112. Brainvectis
113. BrainX
114. Brisco Capital Partners
115. Bristol Myer Squibb
116. Britannia Pharmaceuticals
117. Broad Institute
118. CAAP Creation
119. Caixa Capital Risc
120. Cantabio Pharmaceuticals
121. Capo Therapeutics
122. Carna Biosciences
123. CarThera
124. Cellix Bio
125. Cenna Biosciences
126. Centogene
127. Cerecin (formerly called Accera)
128. Cerecor
129. CereSpir
130. Cerevance
131. CHA Biotech
132. Changchun Huayang High-tech
133. Chaperone Therapeutics
134. Chipscreen
135. Chronos Therapeutics
136. CinnaGen
137. Cipio Partners
138. Clera
139. Clevexel
140. CNRS Innovation
141. Cobra Biologics
142. Cogentis Therapeutics
143. Cognition Therapeutics
144. Cognosci
145. Collaborative Medicinal Development
146. Columbia University
147. Comtan
148. Contera Pharma
149. CoPlex Therapeutics
150. Corium International
151. Cornell University
152. Cortexyme
153. Cortice Biosciences
154. Corvitex
155. Crinetics Pharmaceuticals
156. CuraSen Therapeutics
157. Curemark
158. Cyclenium Pharma
159. DAE HWA Pharmaceutical
160. Daewoong Pharmaceutical
161. Dainippon Sumitomo Pharma
162. Dart Pharma
163. Debiopharm
164. Deciphera Pharmaceuticals
165. DEKK-TEC
166. DelMar Pharmaceuticals
167. Denali Therapeutics
168. DermaXon
169. Dexcom
170. Domain Therapeutics
171. Dong-A ST
172. Edunn Biotechnology
173. Eight Roads
174. EIP Pharma
175. Eisai
176. Elan Pharmaceuticals
177. Eli Lilly
178. Elron Electronic Industries
179. EMD Serono
180. EMulate Therapeutics
181. EnhanX Biopharm
182. Enterin
183. E-Scape Bio
184. Ethris
185. Eureka Eurostars
186. Evercore
187. Evgen Pharma
188. Fabre-Kramer Pharmaceutical
189. Federal Ministry of Education and Research
190. FerroKin BioSciences
191. Fidelity Biosciences
192. FightMND
193. Financière Tuileries
194. Flagship Ventures
195. Flocel
196. Fluorinov Pharma
197. Fondazione Telethon
198. Forest laboratories (a division of Allergan)
199. F-star
200. FUJIFILM Toyama Chemical
201. Fulcrum Therapeutics
202. Fundación MEDINA
203. Gale Capital Solutions
204. GemVax & Kael
205. Gene Therapy Research Institution
206. Genentech
207. Genervon Biopharmaceuticals
208. Genzyme
209. German Cancer Research Center
210. Gismo Therapeutics
211. GlaxoSmithKline
212. GliaCure
213. GliaPharm
214. GNT Pharma
215. Goldman Sachs
216. Grifols
217. Group Arnault
218. H. Lundbeck A/S
219. Halozyme Therapeutics
220. Haplogen
221. Harvard University
222. Herantis Pharma
223. Heritage Pharmaceuticals
224. HSRx Biopharmaceutical
225. IACTA Pharmaceuticals
226. ICBI
227. IlDong Pharmaceutical
228. Immune Pharmaceuticals
229. Immunex
230. Immungenetics
231. Impax Laboratories
232. Impel NeuroPharma
233. ImStar
234. Industrial Technology Research Institute
235. Inflazome
236. Inhibikase Therapeutics
237. Innovate UK
238. Innovative California Biosciences International (ICBI)
239. INSERM-CEA
240. Institute for Research in Immunology and Cancer — Commercialization of Research
241. Intec Pharma
242. Integrative Research Laboratories
243. IntelGenx
244. Intellect Neurosciences
245. International Stem Cell Corp
246. Intra-Cellular Therapies
247. INVENT Pharmaceuticals
248. Investments for the Future Program
249. Io Therapeutics
250. Ionis Pharmaceuticals
251. Iproteos
252. IRB Barcelona
253. Janssen Pharmaceuticals (part of Johnson & Johnson Innovation)
254. Jazz Pharmaceuticals
255. JCR Pharmaceuticals
256. JEIL Pharmaceuticals
257. Johns Hopkins University
258. Johnson & Johnson
259. Johnson and Johnson Development
260. Jonghoud International
261. Junaxo
262. Kadmon
263. Kainos Medicine
264. KalGene Pharmaceuticals
265. Karuna Pharmaceuticals
266. Khondrion
267. Kinled Holding
268. KISSEI Pharmaceuticals
269. Korea Drug Development Fund (KDDF)
270. K-PAX Pharmaceuticals
271. Krisani Bio
272. Kyowa Kirin
273. Lauren Sciences
274. Leland Stanford Junior University
275. Leiden University
276. Lipopharma
277. Living Cell Technologies
278. Lixte Biotechnology
279. Longeveron
280. Longevity Biotech
281. Lonza
282. Lotus Tissue
283. Lumena Pharmaceuticals
284. Lundbeck
285. Luye Pharma Group
286. Lyndra Therapeutics
287. Lysosomal Therapeutics
288. M3 Biotechnology
289. Massachusetts Institute of Technology
290. McGill University
291. Med Life Discoveries
292. MedDay Pharmaceuticals
293. Medesis Pharma
294. MedGenesis Therapeutix
295. MedImmune
296. Medipost
297. Mediti Pharma
298. Medtronic
299. Melior Pharmaceuticals
300. Merck
301. Metabolic Solutions Development Company
302. Michael J Fox Foundation
303. Michael Smiths Laboratories
304. Minerva Neurosciences
305. Minoryx Therapeutics
306. Mirapex
307. Mireca Medicines
308. Mission Therapeutics
309. Mitochon Pharmaceuticals
310. Mitsui Global Investment
311. MMV Financial
312. MMV Financial
313. Moderna Therapeutics
314. Momenta Pharmaceuticals / Sandoz
315. Montisera
316. Morgan Stanley
317. Morphotek
318. Movetis
319. Mylan
320. Mylan Laboratories
321. Mystic Pharmaceuticals
322. naNO LIMIT Therapeutics
323. Nanomerics
324. National Cancer Institute
325. National MS Society
326. National Research Council of Canada Industrial Research Assistance Program
327. Nature Cell Biology
328. Nektar Therapeutics
329. Neomed Institute of Wellness and Rehabilitation
330. Netherlands Translational Research Center
331. Neupro
332. Neuralstem
333. Neuraltus Pharmaceuticals
334. Neuren Pharmaceuticals
335. Neurim Pharmaceuticals
336. NeuroAdjuvants
337. Neurocentria
338. Neurocrine Biosciences
339. NeuroDerm
340. Neurodon
341. Neurogeneration
342. NeuroGenetic Pharmaceuticals
343. Neurolixis
344. Neuron Bio
345. Neuronascent
346. Neuronix
347. NeurOp
348. Neuropore Therapies
349. NeuroSolis
350. Neurotez
351. NeuroTransit
352. Neurotrope Bioscience
353. NeuroVive Pharmaceutical
354. Neuway Pharma
355. NEUWAY Pharma
356. New World Laboratories
357. NewGen Therapeutics
358. NexGenix
359. NextSource Biotechnology
360. nLife Therapeutics
361. NLS Pharma
362. Nordic Life Sciences
363. Novartis
364. Novo Nordisk
365. Novogen
366. NPS Pharmaceuticals
367. Nsgene
368. Ocrevus
369. Oligomerix
370. Oncodesign
371. OncoNanoBBB
372. Ono Pharmaceutical
373. Opko Curna
374. OPKO Health
375. OptiNose
376. Orion Pharma
377. Ortho-McNeil Pharmaceutical
378. Oryzon Genomics
379. Osmotica Pharmaceutical
380. Ossianix
381. Otsuka Pharmaceutical
382. Oxalys Pharmaceuticals
383. Oxford BioMedica
384. P2D Bioscience
385. Pain Therapeutics
386. Palobiofarma
387. Panakès Partners
388. Pangu Biopharma
389. Parc Cientific de Barcelona
390. Parke-Davis
391. PeptiDream
392. Peptron
393. Perfusion Technology
394. Pervasis Therapeutics
395. Pfizer
396. Pharma Two B
397. Pharmacia & Upjohn
398. Pharmaphenix
399. Pharmidex
400. Pharnext
401. Pitango Venture Capital
402. Pitango Venture Capital
403. Plex Pharmaceuticals
404. Plexxikon
405. Portage Pharmaceuticals
406. Prana Biotechnology
407. Premacure
408. Prexton Therapeutics
409. Priavoid
410. Primary Peptides
411. Probiodrug
412. Proclara Biosciences
413. ProMIS Neurosciences
414. Promius Pharma
415. Protagenic Therapeutics
416. ProteoTech
417. Prothena
418. Protheragen
419. PTC Therapeutics
420. QR Pharma
421. Radio Medix
422. Radius Health
423. Raptor
424. RaQualia
425. Regenera Pharma
426. RemeGenix
427. reMYND
428. Repligen
429. Requip
430. Retrotope
431. Rett Syndrome Research Trust
432. Reviva Pharmaceuticals
433. Roche
434. Rodin Therapeutics
435. Sage Therapeutics
436. Sagetis Biotech
437. SalubRx Therapeutics
438. Sangamo Therapeutics
439. Saniona
440. Sanofi
441. Santaris Pharma
442. Saol
443. Schering
444. Schering-Plough
445. Schwarz Pharma
446. SciFluor Life Sciences
447. SCR Provençale et Corse
448. Serina Therapeutics
449. Servier
450. Sham Innovation Santé
451. Shanghai Green valley Pharmaceutical
452. Shire
453. Siena Biotech
454. Sihuan Pharmaceutical
455. SiMPore
456. SiNON Therapeutics (formerly known as nano LIMIT Therapeutics)
457. Sinphar Pharmaceuticals
458. SK Biopharmaceuticals
459. SmithKline Beecham
460. Société de Capital
461. Solvo Biotechnology
462. Sosei Heptares
463. Southern Research
464. Sovicell
465. Spanish Ministry of Economy
466. Spark Therapeutics
467. Stern Investor Relations
468. Sumitomo Dainippon Pharma
469. Sun Pharma Advanced Research Company
470. Sunovion
471. Supernova Invest
472. Suven Life Sciences
473. Synageva BioPharma
474. Synapse Technologies
475. SynVivo
476. T3D Therapeutics
477. Tactical Therapeutics
478. Takeda Pharmaceuticals
479. Takeda Ventures
480. Tasmar
481. TauRx Therapeutics
482. TechnoPhage
483. Teikoku Pharma
484. Tetra Discovery Partners
485. Teva Pharmaceutical
486. The ALS Association
487. The Campbell Foundation
488. The Hospital for Sick Children
489. Titan Pharmaceuticals
490. Tonix Pharmaceuticals
491. TPG Biotech
492. TransBioTech
493. Transgene
494. Transition Therapeutics
495. TransMolecular
496. Treventis
497. TTY Biopharm
498. UCB
499. United Neuroscience
500. University College London
501. University of Barcelona
502. University of British Columbia
503. University of California
504. University of Connecticut
505. University of Sherbrooke
506. University of Texas
507. University of Washington
508. Uppsala University
509. US WorldMeds
510. Vall d’Hebron Research Institute
511. Vect-Horus
512. VIMAC Milestone Medica Fund
513. Vinnova
514. ViroPharma
515. VistaGen Therapeutics
516. Vivreon Biosciences
517. Voices Against Brain Cancer
518. VoltMed
519. Voyager Therapeutics
520. Wellington Partners
521. WuXi Biologics
522. Xcelthera
523. Xenoport
524. Xinogen
525. Xoc Pharmaceuticals
526. Zambon
527. Zywie


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of the Human Brain
3.3. Global Burden of Neurological Disorders
3.4. Strategies for Drug Delivery to the Central Nervous System (CNS)
3.4.1. Invasive Techniques
3.4.1.1. Systemic Administration of Therapeutics
3.4.1.2. Direct Administration of Therapeutics
3.4.1.3. Intracerebral Devices and Implants
3.4.2. Non-Invasive Techniques / Approaches
3.4.2.1. Liposomes
3.4.2.2. Exosomes
3.4.2.3. Prodrugs
3.4.2.4. Nanoparticles and Microspheres
3.4.2.5. Novel Formulations and Conjugates
3.4.3. Chemical Delivery Systems
3.5. Blood-Brain Barrier (BBB)
3.5.1. Key Historical Milestones
3.5.2. Structure and Key Components
3.5.3. Key Functions
3.6. Strategies for Drug Delivery across the BBB
3.6.1. Increasing Permeability by Temporary Disruption of the BBB
3.6.2. Pharmacological Strategies to Facilitate Transport Across the BBB
3.7. Challenges Associated with BBB Penetration and CNS Drug Delivery
3.8. Prevalent Trends Related to Non-Invasive BBB Penetration Technologies
3.8.1. Emerging Focus Areas
3.8.2. Key Historical Trends
3.8.3. Geographical Activity
3.9. Concluding Remarks
4. MARKET LANDSCAPE: NON-INVASIVE BBB PENETRATION TECHNOLOGIES
4.1. Chapter Overview
4.2. Non-Invasive BBB Penetration Technologies: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Underlying Principle
4.2.3. Analysis by Compatible Pharmacological Molecule(s)
4.2.4. Analysis by Target Receptor(s)
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Patent Availability
4.2.7. Analysis by Licensing Activity
4.3. Non-Invasive BBB Penetration Technology Providers: Overall Market Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
5. MARKET LANDSCAPE: BBB PENETRATING DRUGS
5.1. Chapter Overview
5.2. BBB Penetrating Drugs: Development Pipeline
5.2.1. Analysis by Phase of Development
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Affiliated BBB Penetration Technology
5.2.4. Analysis by Route of Administration
5.2.5. Analysis by Target Disease Indication(s)
5.2.6. Analysis by Therapeutic Area(s)
5.3. BBB Penetrating Drugs: Additional Information
5.4. BBB Penetrating Drug Developers: Overall Market Landscape
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Location of Headquarters
5.4.4. Leading Drug Developers: Analysis by Number of Drugs
5.4.5. Leading Drug Developers: 4D Bubble Analysis based on Pipeline Strength, Target Disease Indication and Company Size
5.4.6. Heptagon Representation: Analysis by Phase of Development and Key Disease Indications
5.4.7. Tree Map Representation: Analysis by Key Disease Indications and Size of the Company
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Leading Players based in North America
6.2.1. Angiochem
6.2.1.1. Company Overview
6.2.1.2. Technology Overview
6.2.1.3. Product Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.2. ArmaGen
6.2.2.1. Company Overview
6.2.2.2. Technology Overview
6.2.2.3. Product Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Denali Therapeutics
6.2.3.1. Company Overview
6.2.3.2. Technology Overview
6.2.3.3. Product Portfolio
6.2.3.4. Recent Developments and Future Outlook
6.2.4. ICB International
6.2.4.1. Company Overview
6.2.4.2. Technology Overview
6.5.4.3. Product Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.2.5. Lauren Sciences
6.2.5.1. Company Overview
6.2.5.2. Technology Overview
6.2.5.3. Product Portfolio
6.2.5.4. Recent Developments and Future Outlook
6.3. Leading Players based in Europe
6.3.1. BioArctic
6.3.1.1. Company Overview
6.3.1.2. Technology Overview
6.3.1.3. Product Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Cyclenium Pharma
6.3.2.1. Company Overview
6.3.2.2. Technology Overview
6.3.2.3. Product Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Iproteos
6.3.3.1. Company Overview
6.3.3.2. Technology Overview
6.3.3.3. Product Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.3.4. Medesis Pharma
6.3.4.1. Company Overview
6.3.4.2. Technology Overview
6.3.4.3. Product Portfolio
6.3.4.4. Recent Developments and Future Outlook
6.3.5. Ossianix
6.3.5.1. Company Overview
6.3.5.2. Technology Overview
6.3.5.3. Product Portfolio
6.3.5.4. Recent Developments and Future Outlook
6.3.6. Vect-Horus
6.3.6.1. Company Overview
6.3.6.2. Technology Overview
6.3.6.3. Product Portfolio
6.3.6.4. Recent Developments and Future Outlook
6.4. Leading Players based in Asia-Pacific
6.4.1. JCR Pharmaceuticals
6.4.1.1. Company Overview
6.4.1.2. Technology Overview
6.4.1.3. Product Portfolio
6.4.1.4. Recent Developments and Future Outlook
7. TECHNOLOGY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Key Parameters
7.3. BBB Penetration Technologies: Platform Competitiveness Analysis
8. NON-INVASIVE BBB PENETRATION TECHNOLOGIES: POPULAR APPROACHES
8.1. Chapter overview
8.2. Receptor Mediated Transcytosis (RMT)
8.2.1. Type of Target Receptors
8.2.1.1. Diphtheria Toxin Receptor
8.2.1.2. Insulin Receptor and Insulin-like Growth Factor Receptor
8.2.1.3. Low Density Lipoprotein Receptor-Related Proteins (LRP-1 and LRP-2)
8.2.1.4. Transferrin Receptor
8.2.2. Types of RMT Approaches
8.2.2.1. Bispecific Antibody-based Approach
8.2.2.2. Molecular Trojan Horse-based Approach
8.2.2.2.1. Important Considerations for Designing Molecular Trojan Horses
8.2.2.2.2. Considerations for Designing a Trojan Horse Liposome (THL)
8.2.2.2.3. Popular Conjugation Strategies
8.2.2.2.3.1. Direct Coupling Approach
8.2.2.2.3.2. Nanoparticles-based Approach
8.3. Increasing the Permeability of the BBB
8.3.1. Use of Ultrasound Waves
8.3.2. Use of High-Frequency Electric Field
8.4. Passive Diffusion
8.5. Novel Approaches
8.5.1. Cell Penetrating Peptides
8.5.2. Macrocycles
8.5.3. Organ-on-a-Chip Technology
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Non-Invasive BBB Technologies and Drugs: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Focus Area
9.3.6. Analysis by Type of Molecule
9.3.7. Analysis by Target Disease Indication
9.3.8. Most Active Players: Analysis by Number of Partnerships
9.3.9. Most Popular Technologies: Analysis by Number of Partnerships
9.3.10. Regional Analysis
9.3.11. Intercontinental and Intracontinental Agreements
10. ANALYSIS OF RECENT LICENSING AGREEMENTS
10.1. Chapter Overview
10.2. Licensing Agreements: Definition and Importance in Pharmaceutical Industry
10.3. Types of Licensing Agreements
10.3.1. Out-Licensing Agreements
10.3.2. In-Licensing Agreements
10.4. Components of Licensing Agreements
10.5. Recent Examples of BBB-Related Technology Licensing Agreements
10.5.1. Analysis by Year of Agreement
10.5.2. Analysis by Type of Licensing Agreement
10.5.3. Analysis by Type of Owner
10.5.4. Most Active Players: Analysis by Number of Licensing Agreements
10.5.5. Most Popular Technologies: Analysis by Number of Licensing Agreements
10.5.6. Regional Analysis
10.5.7. Intercontinental and Intracontinental Licensing Agreements
10.6. Case-in-Point: Technology Licensing Timeline
10.6.1. Sumitomo Dainippon Pharma and JCR Pharmaceuticals
10.6.2. Denali Therapeutics and Sanofi
10.6.3. biOasis Technologies and Prothena
10.6.4. Vect-Horus and Janssen Pharmaceuticals
10.7. Concluding Remarks
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Non-Invasive BBB Penetration Technologies and Drugs: List of Funding and Investments
11.3.1. Analysis by Number of Instances
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Type of Company
11.3.5. Analysis by Purpose of Funding
11.3.6. Analysis by Type of Molecule
11.3.7. Analysis by Target Disease Indication
11.3.8. Analysis by Geography
11.3.9. Most Active Players: Analysis by Number of Funding Instances
11.3.10. Most Popular Technologies: Analysis by Number of Funding Instances
11.3.11. Most Active Investors: Analysis by Number of Funding Instances
11.4. Concluding Remarks
12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Non-Invasive BBB Penetration Technologies: Patent Analysis
12.3.1. Analysis by Application Year
12.3.1.1. Analysis by Filed Patent Applications
12.3.1.2. Analysis by Granted Patent Applications
12.3.2. Analysis by Issuing Authority / Patent Offices Involved
12.3.3. Analysis by CPC Symbols
12.3.4. Emerging Focus Areas
12.3.5. Analysis by Type of Organization
12.3.6. Leading Assignees: Analysis by Number of Patents
12.4. Non-Invasive BBB Technologies: Patent Valuation Analysis
13. DRUG DEVELOPMENT STRATEGY ANALYSIS
13.1. Chapter Overview
13.2 Scope and Methodology
13.3. Strategies Adopted by Late-Stage Drug Candidates
13.3.1. Drug A
13.3.2. Drug B
13.3.3. Drug C
13.3.4. Drug D
13.4. Concluding Remarks
14. MARKET POTENTIAL OF KEY NEUROLOGICAL DISORDERS
14.1. Chapter Overview
14.2. Market Potential of Key Neurological Disorders: 3D Bubble Chart Analysis
14.3. Key Neurological Disorders: Detailed Information
14.3.1. Alzheimer’s Disease
14.3.1.1. Disease Description
14.3.1.2. Epidemiology
14.3.1.3. Symptoms
14.3.1.4. Current Treatment Options
14.3.1.5. BBB Penetrating Drugs for Alzheimer’s Disease
14.3.1.6. Roots Analysis Perspective
14.3.2. Brain Cancer
14.3.2.1. Disease Description
14.3.2.2. Epidemiology
14.3.2.3. Symptoms
14.3.2.4. Current Treatment Options
14.3.2.4.1. Surgery
14.3.2.4.2. Radiation Therapy
14.3.2.4.3. Systemic Therapy
14.3.2.5. BBB Penetrating Drugs for Brain Cancer
14.3.2.6. Roots Analysis Perspective
14.3.3. Multiple Sclerosis
14.3.3.1. Disease Description
14.3.3.2. Epidemiology
14.3.3.3. Symptoms
14.3.3.4. Current Treatment Options
14.3.3.4.1. Treatment for Attacks
14.3.3.4.2. Treatments to Modify Progression
14.3.3.4.3. Interferons
14.3.3.5. BBB Penetrating Drugs for Multiple Sclerosis
14.3.3.6. Roots Analysis Perspective
14.3.4. Parkinson’s Disease
14.3.4.1. Disease Description
14.3.4.2. Epidemiology
14.3.4.3. Symptoms
14.3.4.4. Current Treatment Options
14.3.4.4.1. Pharmacological Management of Parkinson’s Disease
14.3.4.4.2. Non-Pharmacological Management of Parkinson’s Disease
14.3.4.4.3. Management of Parkinson’s Disease using Dietary Supplements
14.3.4.5. BBB Penetrating Drugs for Parkinson’s Disease
14.3.4.6. Roots Analysis Perspective
15. LIKELY PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Potential Strategic Partners for Drug Development
15.3.1. Opportunities in North America
15.3.1.1. Most Likely Partners
15.3.1.2. Likely Partners
15.3.1.3. Less Likely Partners
15.3.2. Opportunities in Europe
15.3.2.1. Most Likely Partners
15.3.2.2. Likely Partners
15.3.2.3. Less Likely Partners
15.3.3. Opportunities in Asia-Pacific and Rest of the World
15.3.3.1. Most Likely Partners
15.3.3.2. Likely Partners
15.3.3.3. Less Likely Partners
16. MARKET FORECAST
16.1. Chapter Overview
16.2. Forecast Methodology and Key Assumptions
16.3. Overall BBB Penetration Technologies Market, 2020-2030
16.3.1. BBB Penetration Technologies Market: Contribution from Upfront Payments, 2020-2030
16.3.2. BBB Penetration Technologies Contribution from Milestone Payments, 2020-2030
16.4. Overall BBB Penetrating Drugs Market, 2020-2030
16.4.1. BBB Penetrating Drugs Market: Distribution by Type of Molecule
16.4.1.1. BBB Penetrating Drugs Market for Small Molecules, 2020-2030
16.4.1.2. BBB Penetrating Drugs Market for Biologics, 2020-2030
16.4.2. BBB Penetrating Drugs Market: Distribution by Target Disease Indication
16.4.2.1. BBB Penetrating Drugs Market for Brain Metastases in Breast Cancer, 2020-2030
16.4.2.2. BBB Penetrating Drugs Market for Glioblastoma Multiforme, 2020-2030
16.4.2.3. BBB Penetrating Drugs Market for Hunter Syndrome, 2020-2030
16.4.2.4. BBB Penetrating Drugs Market for Hurler Syndrome, 2020-2030
16.4.3. BBB Penetrating Drugs Market: Distribution by Key Geographical Regions
16.4.3.1. BBB Penetrating Drugs Market in North America, 2020-2030
16.4.3.2. BBB Penetrating Drugs Market in Europe, 2020-2030
16.4.3.3. BBB Penetrating Drugs Market in Asia-Pacific and Rest of the World, 2020-2030
16.4.4. BBB Penetrating Drugs Market: Distribution by Leading Technology Platforms
16.4.5. BBB Penetrating Drugs Market: Distribution by Leading Drug Developers
16.5.6. Drug-wise Sales Forecast
16.5.6.1. 2B3-101 / 2X-111 (2X Oncology)
16.5.6.1.1. Sales Forecast (USD Million)
16.5.6.1.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.1.3. Net Present Value (USD Million)
16.5.6.1.4. Value Creation Analysis
16.5.6.2. AGT-181 (ArmaGen)
16.5.6.2.1. Sales Forecast (USD Million)
16.5.6.2.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.2.3. Net Present Value (USD Million)
16.5.6.2.4. Value Creation Analysis
16.5.6.3. AGT-182 (ArmaGen)
16.5.6.3.1. Sales Forecast (USD Million)
16.5.6.3.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.3.3. Net Present Value (USD Million)
16.5.6.3.4. Value Creation Analysis
16.5.6.4. ANG1005 (Angiochem)
16.5.6.4.1. Sales Forecast (USD Million)
16.5.6.4.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.4.3. Net Present Value (USD Million)
16.5.6.4.4. Value Creation Analysis
16.5.6.5. JR-141 (JCR Pharmaceuticals)
16.5.6.5.1. Sales Forecast (USD Million)
16.5.6.5.2. Risk-Adjusted Market Opportunity (USD Million)
16.5.6.5.3. Net Present Value (USD Million)
16.5.6.5.4. Value Creation Analysis
17. CONCLUSION
17.1. Chapter Overview
17.2. Key Takeaways
18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Innovative California Biosciences International (ICBI)
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder
18.3. Ossianix
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Frank S Walsh, Chief Executive Officer and Founder
18.4. 2-BBB
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Pieter Gaillard, Chief Executive Officer and Co-Founder
18.5. ArmaGen
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer
18.6. biOasis Technologies
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Rob Hutchison, Chief Executive Officer
18.7. Cyclenium Pharma
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Mark L Peterson, Chief Operating Officer
18.8. Sagetis Biotech
18.8.1. Company Snapshot
18.8.2. Interview Transcript: Xavier Rivero, Chief Operating Officer
18.9. CarThera
18.9.1. Company Snapshot
18.9.2. Interview Transcript: Carole Desseaux, Head of Clinical Affairs
18.10. Vect-Horus
18.10.1. Company Snapshot
18.10.2. Interview Transcript: Jamal Temsamani, Head of Drug Development
18.11. Wyss Institute, Harvard University
18.11.1. Organization Snapshot
18.11.2. Interview Transcript: Kevin Kit Parker, Professor
19. APPENDIX I: TABULATED DATA
20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Structure of the Human Brain
Figure 3.2 Common Neurological Disorders
Figure 3.3 Important Statistics Related to Neurological Disorders
Figure 3.4 Strategies for Drug Delivery to the Central Nervous System (CNS)
Figure 3.5 Key Historical Milestones in BBB Research
Figure 3.6 Pathway Associated with the BBB
Figure 3.7 Transport Systems Associated with the BBB
Figure 3.8 Google Trends Analysis: Emerging Focus Areas
Figure 3.9 Google Trends Analysis: Historical Timeline
Figure 3.10 Google Trends Analysis: Geographical Activity
Figure 4.1 Non-Invasive BBB Penetration Technologies: Distribution by Status of Development
Figure 4.2 Non-Invasive BBB Penetration Technologies: Distribution by Underlying Principle
Figure 4.3 Non-Invasive BBB Penetration Technologies: Distribution by Compatible Pharmacological Molecule(s)
Figure 4.4 Non-Invasive BBB Penetration Technologies: Distribution by Target Receptor(s)
Figure 4.5 Non-Invasive BBB Penetration Technologies: Distribution by Target Disease Indication(s)
Figure 4.6 Non-Invasive BBB Penetration Technologies: Distribution by Patent Availability
Figure 4.7 Non-Invasive BBB Penetration Technologies: Distribution by Licensing Activity
Figure 4.8 Non-Invasive BBB Technology Providers: Distribution by Year of Establishment
Figure 4.9 Non-Invasive BBB Technology Providers: Distribution by Company Size
Figure 4.10 Non-Invasive BBB Technology Providers: Distribution by Location of Headquarters
Figure 5.1 BBB Penetrating Drugs: Distribution by Phase of Development
Figure 5.2 BBB Penetrating Drugs: Distribution by Type of Molecule
Figure 5.3 BBB Penetrating Drugs: Distribution by Affiliated BBB Penetration Technology
Figure 5.4 BBB Penetrating Drugs: Distribution by Route of Administration
Figure 5.5 BBB Penetrating Drugs: Distribution by Target Disease Indication(s)
Figure 5.6 BBB Penetrating Drugs: Distribution by Therapeutic Area(s)
Figure 5.7 BBB Penetrating Drug Developers: Distribution by Year of Establishment
Figure 5.8 BBB Penetrating Drug Developers: Distribution by Company Size
Figure 5.9 BBB Penetrating Drug Developers: Distribution by Location of Headquarters
Figure 5.10 Leading Drug Developers: Distribution by Number of Drugs
Figure 5.11 Leading Drug Developers: 4D Bubble Analysis based on Pipeline Strength, Target Disease Indication and Company Size
Figure 5.12 Heptagon Representation: Distribution by Phase of Development and Key Disease Indications
Figure 5.13 Tree Map Representation: Distribution by Key Disease Indications and Size of the Company
Figure 7.1 BBB Penetration Technologies: Platform Competitiveness Analysis
Figure 8.1 Receptor Mediated Transcytosis (RMT): Key Functions
Figure 8.2 RMT: Working Mechanism
Figure 8.3 Molecular Trojan Horse-based Approach: Working Mechanism
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2014-Q1 2020
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Partner and Partnership Model
Figure 9.7 Partnerships and Collaborations: Distribution by Focus Area
Figure 9.8 Partnerships and Collaborations: Distribution by Type of Molecule
Figure 9.9 Partnerships and Collaborations: Year-Wise Trend by Type of Molecule
Figure 9.10 Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 9.11 Partnerships and Collaborations: Year-Wise Trend by Target Disease Indication
Figure 9.12 Partnerships and Collaborations: Distribution by Target Disease Indication and Partnership Model
Figure 9.13 Most Active Players: Distribution by Number of Partnerships
Figure 9.14 Most Popular Technologies: Distribution by Number of Partnerships
Figure 9.15 Partnerships and Collaborations: Regional Distribution
Figure 9.16 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Key Risks and Benefits Associated with a Licensee
Figure 10.2 Key Risks and Benefits Associated with a Licensor
Figure 10.3 Licensing Agreements: Distribution of Financial Components
Figure 10.4 BBB-Related Technology Licensing Agreements: Cumulative Year-Wise Trend, Pre-2014-Q1 2020
Figure 10.5 BBB-Related Technology Licensing Agreements: Distribution by Type of Licensing Agreement
Figure 10.6 BBB-Related Technology Licensing Agreements: Distribution by Type of Owner
Figure 10.7 Most Active Players: Distribution by Number of Licensing Agreements
Figure 10.8 BBB-Related Technology Licensing Agreements: Regional Analysis
Figure 10.9 BBB-Related Technology Licensing Agreements: Intercontinental and Intracontinental Agreements
Figure 10.10 BBB-Related Technology Licensing Agreements: Technology Providers’ Perspective
Figure 11.1 Funding and Investment Analysis: Distribution of Companies by Year of Establishment and Type of Funding, Pre-2014-Q1 2020
Figure 11.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2014-Q1 2020
Figure 11.3 Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, Pre-2014-Q1 2020
Figure 11.4 Funding and Investment Analysis: Cumulative Amount Invested, Pre-2014-Q1 2020 (USD Million)
Figure 11.5 Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, Pre-2014-Q1 2020 (USD Million)
Figure 11.6 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2014-Q1 2020
Figure 11.7 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, Pre-2014-Q1 2020 (USD Million)
Figure 11.8 Funding and Investment Analysis: Summary of Amount Invested, Pre-2014-Q1 2020 (USD Million)
Figure 11.9 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, Pre-2014-Q1 2020 (USD Million)
Figure 11.10 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, Pre-2014-Q1 2020 (USD Million)
Figure 11.11 Funding and Investment Analysis: Distribution of Instances by Type of Molecule, Pre-2014-Q1 2020
Figure 11.12 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Molecule, Pre-2014-Q1 2020 (USD Million)
Figure 11.13 Funding and Investment Analysis: Distribution by Target Disease Indication
Figure 11.14 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Disease Indication, Pre-2014-Q1 2020 (USD Million)
Figure 11.15 Funding and Investment Analysis: Distribution by Geography
Figure 11.16 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, Pre-2014-Q1 2020
Figure 11.17 Most Active Players: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Figure 11.18 Most Active Technologies: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Figure 11.19 Most Active Investors: Distribution by Number of Funding Instances
Figure 11.20 Funding and Investment Summary, Pre-2014-Q1 2020 (USD Million)
Figure 12.1 Patent Portfolio: Distribution by Type of Patent
Figure 12.2 Patent Portfolio: Cumulative Distribution by Application Year, 2011-2019
Figure 12.3 Patent Portfolio: Distribution of Filed Patents by Application Year, 2011-2019
Figure 12.4 Patent Portfolio: Distribution of Granted Patents by Application Year, 2011-2019
Figure 12.5 Patent Portfolio: Distribution by Issuing Authority / Patent Offices Involved
Figure 12.6 Patent Portfolio: Distribution by CPC Symbols
Figure 12.7 Patent Portfolio: Emerging Focus Areas
Figure 12.8 Patent Portfolio: Cumulative Distribution by Type of Organization
Figure 12.9 Leading Patent Assignees: Distribution by Number of Patents
Figure 12.10 Patent Portfolio: Leading Non-Industry Players in Terms of Number of Patents
Figure 12.11 Patent Portfolio: Distribution by Patent Age (2000-2019)
Figure 12.12 Patent Portfolio: Distribution based on Proprietary Scoring Criteria
Figure 12.13 Patent Portfolio: Valuation Analysis
Figure 13.1 Commercial Development Strategies Adopted for Drug A
Figure 13.2 Commercial Development Strategies Adopted for Drug B
Figure 13.3 Commercial Development Strategies Adopted for Drug C
Figure 13.4 Commercial Development Strategies Adopted for Drug D
Figure 13.5 BBB Penetrating Drug Developers: Popular Development Strategies
Figure 14.1 Market Potential of Key Neurological Disorders: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 14.2 Normal Brain versus Diseased Brain
Figure 14.3 Alzheimer’s Disease: Phases of Disease Progression
Figure 14.4 Global Dementia-Related Statistics: 2015 and 2030 (Millions)
Figure 14.5 Alzheimer’s Disease: Signs and Symptoms
Figure 14.6 Alzheimer’s Disease: Dietary Supplements
Figure 14.7 Market Potential of Alzheimer’s Disease: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 14.8 Brain Cancer: Signs and Symptoms
Figure 14.9 Market Potential of Brain Cancer: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 14.10 Multiple Sclerosis: Signs and Symptoms
Figure 14.11 Market Potential of Multiple Sclerosis: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 14.12 Parkinson’s Disease: Causal Environmental Factors
Figure 14.13 Parkinson’s Disease: Gender-wise Incidence Rates
Figure 14.14 Parkinson’s Disease: Disease Stages
Figure 14.15 Parkinson’s Disease: Motor Symptoms
Figure 14.16 Parkinson’s Disease: Secondary Symptoms
Figure 14.17 Parkinson’s Disease Management: Non-Pharmacological Treatment Options
Figure 14.18 Parkinson’s Disease Management: Surgical Methods
Figure 14.19 Parkinson’s Disease Management: Dietary Supplements
Figure 14.20 Market Potential of Parkinson’s Disease: 3D Bubble Analysis based on Number of Approved Drugs, Pipeline Strength and Target Patient Population
Figure 16.1 Technology Licensing: Distribution of Financial Components
Figure 16.2 Technology Licensing: Likely Market Evolution
Figure 16.3 BBB Penetration Technologies: Average Volume and Value of Upfront Payments (Units, USD Million)
Figure 16.4 BBB Penetration Technologies: Average Volume and Value of Milestone Payments (Units, USD Million)
Figure 16.5 Overall BBB Penetration Technologies Market, 2020-2030 (USD Million)
Figure 16.6 Overall BBB Penetrating Drugs Market, 2020-2030 (USD Million)
Figure 16.7 BBB Penetrating Drugs Market: Distribution by Type of Molecule, 2020 and 2030
Figure 16.8 BBB Penetrating Drugs Market for Small Molecules, 2020-2030 (USD Million)
Figure 16.9 BBB Penetrating Drugs Market for Biologics, 2020-2030 (USD Million)
Figure 16.10 BBB Penetrating Drugs Market: Distribution by Target Disease Indication, 2020 and 2030
Figure 16.11 BBB Penetrating Drugs Market for Brain Metastases in Breast Cancer, 2020-2030 (USD Million)
Figure 16.12 BBB Penetrating Drugs Market for Glioblastoma Multiforme, 2020-2030 (USD Million)
Figure 16.13 BBB Penetrating Drugs Market for Hunter Syndrome, 2020-2030 (USD Million)
Figure 16.14 BBB Penetrating Drugs Market for Hurler Syndrome, 2020-2030 (USD Million)
Figure 16.15 BBB Penetrating Drugs Market: Distribution by Key Geographical Regions, 2020 and 2030
Figure 16.16 BBB Penetrating Drugs Market in North America, 2020-2030 (USD Million)
Figure 16.17 BBB Penetrating Drugs Market in Europe, 2020-2030 (USD Million)
Figure 16.18 BBB Penetrating Drugs Market in Asia-Pacific and Rest of the World, 2020-2030 (USD Million)
Figure 16.19 BBB Penetrating Drugs Market: Distribution by Leading Technology Platforms, 2020 and 2030
Figure 16.20 BBB Penetrating Drugs Market: Distribution by Leading Drug Developers, 2020 and 2030
Figure 16.21 2B3-101 / 2X-111 (2X Oncology): Sales Forecast, till 2030 (USD Million)
Figure 16.22 2B3-101 / 2X-111 (2X Oncology): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Figure 16.23 AGT-181 (ArmaGen): Sales Forecast, till 2030 (USD Million)
Figure 16.24 AGT-181 (ArmaGen): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Figure 16.25 AGT-182 (ArmaGen): Sales Forecast, till 2030 (USD Million)
Figure 16.26 AGT-182 (ArmaGen): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Figure 16.27 ANG1005 (Angiochem): Sales Forecast, till 2030 (USD Million)
Figure 16.28 ANG1005 (Angiochem): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Figure 16.29 JR-141 (JCR Pharmaceuticals): Sales Forecast, till 2030 (USD Million)
Figure 16.30 JR-141 (JCR Pharmaceuticals): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
LIST OF TABLES
Table 3.1 Key Components of the Human Brain
Table 3.2 Commercially Available Devices for CNS Drug Delivery
Table 3.3 Key Differences: Non-Invasive and Invasive BBB Technologies
Table 3.4 List of Key Constituents of the BBB
Table 3.5 Key Functions of the BBB
Table 3.6 List of Blood to Brain Transporters
Table 4.1 Non-Invasive BBB Penetration Technologies: List of Technology Platforms
Table 4.2 Non-Invasive BBB Penetration Technologies: List of Technology Providers
Table 5.1 BBB Penetrating Drugs: Development Pipeline
Table 5.2 BBB Penetrating Drugs: Additional Information
Table 5.3 BBB Penetrating Drugs: List of Drug Developers
Table 6.1 Non-Invasive BBB Penetration Technologies and Drugs: List of Companies Profiled
Table 6.2 Angiochem: Company Overview
Table 6.3 Angiochem: Product Portfolio
Table 6.4 Angiochem: Recent Developments and Future Outlook
Table 6.5 ArmaGen: Company Overview
Table 6.6 ArmaGen: Product Portfolio
Table 6.7 ArmaGen: Recent Developments and Future Outlook
Table 6.8 Denali Therapeutics: Company Overview
Table 6.9 Denali Therapeutics: Product Portfolio
Table 6.10 Denali Therapeutics: Recent Developments and Future Outlook
Table 6.11 ICB International: Company Overview
Table 6.12 ICB International: Product Portfolio
Table 6.13 ICB International: Recent Developments and Future Outlook
Table 6.14 Lauren Sciences: Company Overview
Table 6.15 Lauren Sciences: Product Portfolio
Table 6.16 Lauren Sciences: Recent Developments and Future Outlook
Table 6.17 BioArctic: Company Overview
Table 6.18 BioArctic: Product Portfolio
Table 6.19 BioArctic: Recent Developments and Future Outlook
Table 6.20 Cyclenium Pharma: Company Overview
Table 6.21 Cyclenium Pharma: Product Portfolio
Table 6.22 Cyclenium Pharma: Recent Developments and Future Outlook
Table 6.23 Iproteos: Company Overview
Table 6.24 Iproteos: Product Portfolio
Table 6.25 Iproteos: Recent Developments and Future Outlook
Table 6.26 Medesis Pharma: Company Overview
Table 6.27 Medesis Pharma: Product Portfolio
Table 6.28 Medesis Pharma: Recent Developments and Future Outlook
Table 6.29 Ossianix: Company Overview
Table 6.30 Ossianix: Product Portfolio
Table 6.31 Ossianix: Recent Developments and Future Outlook
Table 6.32 Vect-Horus: Company Overview
Table 6.33 Vect-Horus: Product Portfolio
Table 6.34 Vect-Horus: Recent Developments and Future Outlook
Table 6.35 JCR Pharmaceuticals: Company Overview
Table 6.36 JCR Pharmaceuticals: Product Portfolio
Table 6.37 JCR Pharmaceuticals: Recent Developments and Future Outlook
Table 9.1 Non-Invasive BBB Penetration Technologies and Drugs: Partnerships and Collaborations, Information on Partnership Type, Year and Type of Partner, till Q1 2020
Table 9.2 Non-Invasive BBB Penetration Technologies and Drugs: Partnerships and Collaborations, Information on Type of Molecule, Target Indication and Focus Area, till Q1 2020
Table 10.1 List of BBB-Related Technology Licensing Agreements, till Q1 2020
Table 10.2 Licensing Agreement Details: Sumitomo Dainippon Pharma and JCR Pharmaceuticals
Table 10.3 Licensing Agreement Details: Denali Therapeutics and Sanofi
Table 10.4 Licensing Agreement Details: biOasis Technologies and Prothena
Table 10.5 Licensing Agreement Details: Vect-Horus and Janssen Pharmaceuticals
Table 11.1 Non-Invasive BBB Penetration Technologies and Drugs: Funding and Investments, Information on Funding Type, Year, Amount and Investor, till Q1 2020
Table 11.2 Non-Invasive BBB Penetration Technologies and Drugs: Funding and Investments, Information on Type of Molecule, Target Indication and Focus Area, till Q1 2020
Table 12.1 Patent Portfolio: Definitions of CPC Symbols
Table 12.2 Patent Portfolio: Most Popular CPC Symbols
Table 14.1 Alzheimer’s Disease: List of Marketed Drugs
Table 14.2 Alzheimer’s Disease: List of BBB Penetrating Drugs
Table 14.3 Brain Cancer: List of Marketed Drugs
Table 14.4 Brain Cancer: List of BBB Penetrating Drugs
Table 14.5 Multiple Sclerosis: List of Marketed Drugs
Table 14.6 Multiple Sclerosis: List of BBB Penetrating Drugs
Table 14.7 Parkinson’s Disease: List of Marketed Drugs
Table 14.8 Parkinson’s Disease: List of BBB Penetrating Drugs
Table 15.1 Opportunities in North America: Most Likely Partners
Table 15.2 Opportunities in North America: Likely Partners
Table 15.3 Opportunities in North America: Less Likely Partners
Table 15.4 Opportunities in Europe: Most Likely Partners
Table 15.5 Opportunities in Europe: Likely Partners
Table 15.6 Opportunities in Europe: Less Likely Partners
Table 15.7 Opportunities in Asia-Pacific and Rest of the World: Most Likely Partners
Table 15.8 Opportunities in Asia-Pacific and Rest of the World: Likely Partners
Table 15.9 Opportunities in Asia-Pacific and Rest of the World: Less Likely Partners
Table 16.1. Technology Licensing Agreements: Tranches of Milestone Payments
Table 16.2. BBB-Related Technology Licensing Agreements: Average Upfront Payments and Average Milestone Payments, Pre-2014-Q1 2020 (USD Million)
Table 16.3. BBB Penetrating Drugs: Promising Drug Candidates
Table 16.4. BBB Penetrating Drugs Forecast Assumptions: Price Estimations in Key Geographies
Table 16.5. 2B3-101 / 2X-111 (2X Oncology): Net Present Value (USD Million)
Table 16.6. 2B3-101 / 2X-111 (2X Oncology): Value Creation Analysis (USD Million)
Table 16.7. AGT-181 (ArmaGen): Net Present Value (USD Million)
Table 16.8. AGT-181 (ArmaGen): Value Creation Analysis (USD Million)
Table 16.9. AGT-182 (ArmaGen): Net Present Value (USD Million)
Table 16.10. AGT-182 (ArmaGen): Value Creation Analysis (USD Million)
Table 16.11. ANG1005 (Angiochem): Net Present Value (USD Million)
Table 16.12. ANG1005 (Angiochem): Value Creation Analysis (USD Million)
Table 16.13. JR-141 (JCR Pharmaceuticals): Net Present Value (USD Million)
Table 16.14. JR-141 (JCR Pharmaceuticals): Value Creation Analysis (USD Million)
Table 17.1 BBB Penetrating Drugs and Technologies: Key Takeaways of the Report
Table 18.1 ICBI: Company Snapshot
Table 18.2 Ossianix: Company Snapshot
Table 18.3 2-BBB: Company Snapshot
Table 18.4 ArmaGen: Company Snapshot
Table 18.5 biOasis Technologies: Company Snapshot
Table 18.6 Cyclenium Pharma: Company Snapshot
Table 18.7 Sagetis Biotech: Company Snapshot
Table 18.8 CarThera: Company Snapshot
Table 18.9 Vect-Horus: Company Snapshot
Table 18.10 Wyss Institute, Harvard University: Company Snapshot
Table 19.1 Important Statistics Related to Neurological Disorders
Table 19.2 Non-Invasive BBB Penetration Technologies: Distribution by Status of Development
Table 19.3 Non-Invasive BBB Penetration Technologies: Distribution by Underlying Principle
Table 19.4 Non-Invasive BBB Penetration Technologies: Distribution by Compatible Pharmacological Molecule(s)
Table 19.5 Non-Invasive BBB Penetration Technologies: Distribution by Target Receptor(s)
Table 19.6 Non-Invasive BBB Penetration Technologies: Distribution by Target Disease Indication(s)
Table 19.7 Non-Invasive BBB Penetration Technologies: Distribution by Patent Availability
Table 19.8 Non-Invasive BBB Penetration Technologies: Distribution by Licensing Activity
Table 19.9 Non-Invasive BBB Technology Providers: Distribution by Year of Establishment
Table 19.10 Non-Invasive BBB Technology Providers: Distribution by Company Size
Table 19.11 Non-Invasive BBB Technology Providers: Distribution by Location of Headquarters
Table 19.12 BBB Penetrating Drugs: Distribution by Phase of Development
Table 19.13 BBB Penetrating Drugs: Distribution by Type of Molecule
Table 19.14 BBB Penetrating Drugs: Distribution by Affiliated BBB Penetration Technology
Table 19.15 BBB Penetrating Drugs: Distribution by Route of Administration
Table 19.16 BBB Penetrating Drugs: Distribution by Target Disease Indication(s)
Table 19.17 BBB Penetrating Drugs: Distribution by Therapeutic Area(s)
Table 19.18 BBB Penetrating Drug Developers: Distribution by Year of Establishment
Table 19.19 BBB Penetrating Drug Developers: Distribution by Company Size
Table 19.20 BBB Penetrating Drug Developers: Distribution by Location of Headquarters
Table 19.21 Leading Drug Developers: Distribution by Number of Drugs
Table 19.22 Heptagon Representation: Distribution by Phase of Development and Key Disease Indications
Table 19.23 Tree Map Representation: Distribution by Key Disease Indications and Size of the Company
Table 19.24 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre--2014-Q1 2020
Table 19.25 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.26 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Table 19.27 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.28 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Table 19.29 Partnerships and Collaborations: Distribution by Type of Partner and Partnership Model
Table 19.30 Partnerships and Collaborations: Distribution by Focus Area
Table 19.31 Partnerships and Collaborations: Distribution by Type of Molecule
Table 19.32 Partnerships and Collaborations: Year-Wise Trend by Type of Molecule
Table 19.33 Partnerships and Collaborations: Distribution by Target Disease Indication
Table 19.34 Partnerships and Collaborations: Year-Wise Trend by Target Disease Indication
Table 19.35 Partnerships and Collaborations: Distribution by Target Disease Indication and Partnership Model
Table 19.36 Most Active Players: Distribution by Number of Partnerships
Table 19.37 Most Popular Technologies: Distribution by Number of Partnerships
Table 19.38 Partnerships and Collaborations: Regional Distribution
Table 19.39 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 19.40 BBB-Related Technology Licensing Agreements: Cumulative Year-Wise Trend, Pre-2014-Q1 2020
Table 19.41 BBB-Related Technology Licensing Agreements: Distribution by Type of Licensing Agreement
Table 19.42 BBB-Related Technology Licensing Agreements: Distribution by Type of Owner
Table 19.43 Most Active Players: Distribution by Number of Licensing Agreements
Table 19.44 BBB-Related Technology Licensing Agreements: Regional Analysis
Table 19.45 BBB-Related Technology Licensing Agreements: Intercontinental and Intracontinental Agreements
Table 19.46 Funding and Investment Analysis: Distribution of Companies by Year of Establishment and Type of Funding, Pre-2014-Q1 2020
Table 19.47 Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2014-Q1 2020
Table 19.48 Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, Pre-2014-Q1 2020
Table 19.49 Funding and Investment Analysis: Cumulative Amount Invested, Pre-2014-Q1 2020 (USD Million)
Table 19.50 Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, Pre-2014-Q1 2020 (USD Million)
Table 19.51 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2014-Q1 2020
Table 19.52 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, Pre-2014-Q1 2020 (USD Million)
Table 19.53 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, Pre-2014-Q1 2020 (USD Million)
Table 19.54 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, Pre-2014-Q1 2020 (USD Million)
Table 19.55 Funding and Investment Analysis: Distribution of Instances by Type of Molecule, Pre-2014-Q1 2020
Table 19.56 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Molecule, Pre-2014-Q1 2020 (USD Million)
Table 19.57 Funding and Investment Analysis: Distribution by Target Disease Indication
Table 19.58 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Disease Indication, Pre-2014-Q1 2020 (USD Million)
Table 19.59 Funding and Investment Analysis: Distribution by Geography
Table 19.60 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, Pre-2014-Q1 2020
Table 19.61 Most Active Players: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Table 19.62 Most Active Technologies: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Table 19.63 Most Active Investors: Distribution by Number of Funding Instances
Table 19.64 Funding and Investment Summary, Pre-2014-Q1 2020 (USD Million)
Table 19.65 Patent Portfolio: Distribution by Type of Patent
Table 19.66 Patent Portfolio: Cumulative Distribution by Application Year, 2011-2019
Table 19.67 Patent Portfolio: Distribution of Filed Patents by Application Year, 2011-2019
Table 19.68 Patent Portfolio: Distribution of Granted Patents by Application Year, 2011-2019
Table 19.69 Patent Portfolio: Distribution by Issuing Authority / Patent Offices Involved
Table 19.70 Patent Portfolio: Distribution by CPC Symbols
Table 19.71 Patent Portfolio: Cumulative Distribution by Type of Organization
Table 19.72 Leading Patent Assignees: Distribution by Number of Patents
Table 19.73 Patent Portfolio: Leading Non-Industry Players in Terms of Number of Patents
Table 19.74 Patent Portfolio: Distribution by Patent Age (2000-2019)
Table 19.75 Patent Portfolio: Valuation Analysis
Table 19.76 Global Dementia-Related Statistics: 2015 and 2030 (Millions)
Table 19.77 BBB Penetration Technologies: Average Volume and Value of Upfront Payments (Units, USD Million)
Table 19.78 BBB Penetration Technologies: Average Volume and Value of Milestone Payments (Units, USD Million)
Table 19.79 Overall BBB Penetration Technologies Market, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.80 Overall BBB Penetrating Drugs Market, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.81 BBB Penetrating Drugs Market: Distribution by Type of Molecule, 2020 and 2030
Table 19.82 BBB Penetrating Drugs Market for Small Molecules, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.83 BBB Penetrating Drugs Market for Biologics, Conservative, Base and Optimistic Scenario, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.84 BBB Penetrating Drugs Market: Distribution by Target Disease Indication, 2020 and 2030
Table 19.85 BBB Penetrating Drugs Market for Brain Metastases in Breast Cancer, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.86 BBB Penetrating Drugs Market for Glioblastoma Multiforme, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.87 BBB Penetrating Drugs Market for Hunter Syndrome, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.88 BBB Penetrating Drugs Market for Hurler Syndrome, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.89 BBB Penetrating Drugs Market: Distribution by Key Geographical Regions, 2020 and 2030
Table 19.90 BBB Penetrating Drugs Market in North America, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.91 BBB Penetrating Drugs Market in Europe, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.92 BBB Penetrating Drugs Market in Asia-Pacific and Rest of the World, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.93 BBB Penetrating Drugs Market: Distribution by Leading Technology Platforms, 2020 and 2030
Table 19.94 BBB Penetrating Drugs Market: Distribution by Leading Drug Developers, 2020 and 2030
Table 19.95 2B3-101 / 2X-111 (2X Oncology): Sales Forecast, till 2030 (USD Million)
Table 19.96 2B3-101 / 2X-111 (2X Oncology): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Table 19.97 AGT-181 (ArmaGen): Sales Forecast, till 2030 (USD Million)
Table 19.98 AGT-181 (ArmaGen): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Table 19.99 AGT-182 (ArmaGen): Sales Forecast, till 2030 (USD Million)
Table 19.100 AGT-182 (ArmaGen): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Table 19.101 ANG1005 (Angiochem): Sales Forecast, till 2030 (USD Million)
Table 19.102 ANG1005 (Angiochem): Risk-Adjusted Market Opportunity, till 2030 (USD Million)
Table 19.103 JR-141 (JCR Pharmaceuticals): Sales Forecast, till 2030 (USD Million)
Table 19.104 JR-141 (JCR Pharmaceuticals): Risk-Adjusted Market Opportunity, till 2030 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook